Goldman Sachs Maintains Buy on Guardant Health, Lowers Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a Buy rating on Guardant Health (NASDAQ:GH) but reduced the price target from $43 to $37.

January 30, 2024 | 1:58 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs reaffirms a Buy rating on Guardant Health but decreases the price target to $37, indicating a potential upside but with caution.
While the Buy rating reaffirms confidence in Guardant Health's prospects, the reduction in the price target may reflect a more conservative outlook on the company's valuation or market conditions. This mixed signal could lead to a neutral short-term impact on the stock as investors digest both the continued endorsement and the lowered expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100